Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.84M | -20.45M | -19.14M | -26.00M | -28.01M |
| Total Depreciation and Amortization | 1.71M | 1.74M | 2.11M | 2.14M | 2.15M |
| Total Amortization of Deferred Charges | 560.50K | 380.80K | 190.40K | 0.00 | 0.00 |
| Total Other Non-Cash Items | 3.91M | 8.58M | 1.15M | 6.53M | 4.85M |
| Change in Net Operating Assets | -3.40M | -4.68M | -2.80M | -3.91M | -2.37M |
| Cash from Operations | -13.06M | -14.43M | -18.49M | -21.24M | -23.38M |
| Capital Expenditure | -241.20K | -284.30K | -310.60K | -301.30K | -73.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -348.30K | -385.00K | -370.40K | -339.10K | -306.70K |
| Cash from Investing | -589.70K | -669.50K | -681.20K | -640.50K | -380.30K |
| Total Debt Issued | 15.00M | 15.00M | 15.00M | 15.00M | -- |
| Total Debt Repaid | -4.38M | -5.00M | -5.00M | -5.00M | -625.00K |
| Issuance of Common Stock | 7.00M | 220.10K | 12.26M | 12.91M | 13.84M |
| Repurchase of Common Stock | -41.50K | -41.50K | -41.50K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -848.00K | -848.00K | -848.00K | -790.40K | -- |
| Cash from Financing | 16.73M | 9.33M | 21.37M | 22.12M | 13.22M |
| Foreign Exchange rate Adjustments | -64.60K | -84.70K | -77.40K | -139.50K | -104.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.02M | -5.85M | 2.12M | 103.60K | -10.64M |